Inventiva S.A.

NASDAQ:IVA

Biotechnology

Healthcare
$3.22 +0.42%

+$0.02 today

Market cap
$167.38M
Beta
0.88
P/E (TTM)
-5.5
EPS (TTM)
-$0.56
52W Low $2.85High $7.98

Volume 2.04M

Average 0.45M

IVA EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Inventiva S.A.NASDAQ: IVA

EBITDA · Q4 FY2025 · quarter ended Dec 2025

EBITDA remains negative

Q4 FY2025 EBITDA was -€77.74M, compared with -€114.71M a year earlier.

Context

  • EBITDA amounted to 2858.6% of revenue in FY2025, up 1048.1 pp from a year earlier.
  • EBITDA grew in size in 2 of the last 3 fiscal years.

What to watch

Whether EBITDA reaches the consensus estimate from 9 analysts of -€116.53M (+9.1%) for the fiscal year ending Dec 2026, a slowdown from the +23.0% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterDec 2025
-€77.74M— QoQ
Last fiscal yearDec 2025
-€128.15M+23.0% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+32.2%——
1 year+23.0%+9.1%-14.0 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

EUR · from the income statement

Latest · FY2025
(128.15M) EUR
Year-over-year change
+23.0%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How IVA compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +23.0% is the 4th highest of 10, against a peer median of +20.1%.
  • EBITDA amounts to 2858.6% of revenue for IVA, versus a peer median of 999.5%.
IVA Competitors
EBITDA for IVA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
EPRXEupraxia Pharmaceuticals Inc.LTM Mar 2026-$45.49M USD-75.7%——
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026-$46.56M USD+46.6%—67.3%
NAUTNautilus Biotechnology, Inc.LTM Mar 2026-$50.77M USD+11.7%——
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026-$52.72M USD+20.1%—161.1%
TNYATenaya Therapeutics, Inc.LTM Mar 2026-$75.47M USD+22.0%—33540.9%
IVVDInvivyd, Inc.LTM Mar 2026-$75.72M USD+45.7%—135.5%
AVTXAvalo Therapeutics, Inc.LTM Mar 2026-$84.35M USD-214.9%—142957.6%
CRBUCaribou Biosciences, Inc.LTM Mar 2026-$111.97M USD+23.4%—999.5%
IVAInventiva S.A.FY2025-€128.15M EUR+23.0%—2858.6%
RNACCartesian Therapeutics, Inc.LTM Mar 2026-$158.55M USD-341.7%—8932.3%
Peer median (excluding IVA) —+20.1%—999.5%

Competitors are the stored peer set for IVA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue4.19M12.18M17.48M9.2M4.48M
Cost of Revenue1.02M995K(23K)3.88M2.8M
Gross Profit4.19M17.06M17.5M9.2M1.51M
Gross Margin100.0%140.1%100.1%100.0%33.7%
Research & Development48.45M60.47M110.01M90.88M83.61M
Selling, General & Admin11.52M15.5M15.61M17.1M53.89M
Operating Expenses56.31M74.17M120.19M106.76M137.37M
Depreciation & Amortization858K870K2.6M5.2M2.8M
EBITDA(52.76M)(56.29M)(102.04M)(166.53M)(128.15M)
EBITDA Margin-1258.0%-462.2%-583.9%-1810.4%-2858.6%
Operating Income(52.11M)(57.11M)(102.71M)(97.56M)(130.95M)
Operating Margin-1242.6%-468.9%-587.7%-1060.6%-2921.0%
Interest Income57K390K945K1.14M2.83M
Interest Expense138K707K5.18M12.18M32.3M
Other Income / Expenses2.84M2.82M(7.11M)(86.34M)(211.38M)
Income Before Tax(49.27M)(54.29M)(109.82M)(183.9M)(342.33M)
Pre-Tax Margin-1174.8%-445.8%-628.4%-1999.4%-7636.1%
Income Tax Expense364K(20K)607K313K22K
Net Income(49.64M)(54.27M)(110.43M)(184.21M)(340.16M)
Net Margin-1183.5%-445.6%-631.8%-2002.7%-7587.8%
EPS (Basic)(1.27)(1.31)(2.43)(3.54)(1.82)
EPS (Diluted)(1.27)(1.31)(2.43)(3.54)(1.82)
Weighted Avg Shares39.17M41.45M45.35M51.98M186.8M
Weighted Avg Shares (Diluted)39.17M41.45M45.35M51.98M186.8M

Inventiva S.A.

NASDAQ:IVA

Intrinsic Alpha fair value

Locked

Current Price

$3.22

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.